Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082082 · ClinicalTrials.gov registry record · Phase 2
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
A Phase 2 study, sponsored by SciClone Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00082082: Completed Phase 2 study, sponsored by SciClone Pharmaceuticals.
NCT00082082 is a Phase 2 study that has completed, run by SciClone Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082082, a Phase 2 study, has completed, sponsored by SciClone Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular carcinoma (HCC).
Interventions
- DRUG Thymalfasin (thymosin alpha-1)
- PROCEDURE Trans arterial chemoembolization (TACE)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00082082 record still lists
NCT00082082 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Thymalfasin (thymosin alpha-1) is the first listed.
NCT00082082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00082082 about?
NCT00082082 is a clinical study titled "A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma". The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular carcinoma (HCC).
What is the current status of trial NCT00082082?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00082082?
The interventions under investigation include: Thymalfasin (thymosin alpha-1) (DRUG), Trans arterial chemoembolization (TACE) (PROCEDURE).
Who is sponsoring clinical trial NCT00082082?
This trial is sponsored by SciClone Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.